HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities
Participation in BIO International Convention 2026 supports HanchorBio’s continued engagement with global biotech, pharmaceutical, and investment partners
[Taipei, Shanghai, San Francisco | June 19, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026, taking place June 22–25, 2026, in San Diego, California.
BIO International Convention is one of the world’s largest biotechnology events, bringing together global leaders from biotechnology, pharmaceuticals, investment, academia, government, and patient advocacy groups to explore innovation, partnerships, and business development opportunities.
Event Information
- Event: BIO International Convention 2026
- Date: June 22–25, 2026
- Location: San Diego Convention Center, San Diego, California, USA
Through BIO Partnering™, HanchorBio looks forward to engaging with global biotech, pharmaceutical, and investment partners. The BIO Partnering™ platform is designed to support efficient one-on-one meeting requests and scheduling, helping participants identify and connect with potential business development partners.
HanchorBio will leverage BIO International Convention 2026 to showcase the progress of its clinically validated innate immune platform and growing pipeline across oncology and autoimmune diseases. The Company looks forward to engaging with global pharmaceutical, biotechnology, and investment partners to explore licensing, co-development, and other strategic collaboration opportunities. With multiple clinical-stage programs advancing across key disease areas, HanchorBio believes the meeting provides an important platform to expand global partnering discussions and support the continued development of its international business strategy.
Guided by its mission of “Reimagining Immunotherapy for Patients Worldwide,” HanchorBio remains committed to advancing Fc-based biologics designed to address important unmet medical needs in cancer and immune-mediated diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory decisions, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康生技將出席 BIO 國際大會 2026，拓展全球合作交流機會
參與 BIO 國際大會 2026持續強化與全球生技、製藥及投資夥伴的深化交流
漢康生技（TWSE: 7827），致力於開發腫瘤與自體免疫疾病下一代免疫療法的全球臨床階段生物科技公司，今日宣布，商發長叢越華博士將出席於美國加州聖地牙哥舉行的 BIO International Convention 2026（BIO 國際大會 2026），會議期間為 2026 年 6 月 22 日至 25 日。
BIO 國際大會為全球具代表性的生物科技產業盛會之一，匯聚來自生技、製藥、投資、學研、政府機構及病患倡議組織等領域的產業領袖，促進創新技術交流、策略合作與商務開發機會。
活動基本資訊
- 活動名稱：BIO International Convention 2026（BIO 國際大會 2026）
- 活動時間：2026 年 6 月 22 日至 25 日
- 活動地點：美國加州聖地牙哥會議中心
漢康生技將透過 BIO Partnering™ 媒合系統，與全球生技、製藥及投資夥伴安排商務開發會議。BIO Partnering™ 為協助與會者邀約與安排商務會議的專業平台，持續優化會議邀約及排程功能，以提升一對一商務交流的效率。
此次參與大會，漢康生技將向國際夥伴介紹其差異化先天免疫平台，以及涵蓋腫瘤、自體免疫疾病與其他免疫相關疾病的產品管線布局。公司期待藉由此全球產業平台，進一步提升國際能見度，深化與潛在合作夥伴的策略對話，並拓展授權、共同開發及全球合作機會。
漢康生技將持續秉持「為全球病患重新定義免疫療法」的使命，推動以 Fc骨幹創新藥為核心的生物藥開發，致力於回應癌症及免疫相關疾病領域尚未被滿足的重大醫療需求。
關於漢康生技
漢康生技（TWSE: 7827）據點涵蓋台北、上海及舊金山灣區，是一家專注於腫瘤免疫與免疫相關疾病的全球臨床階段生物科技公司。公司由具備生物藥發現與全球開發經驗的團隊領導，致力於重塑癌症治療格局。漢康生技專有 Fc-based designer biologics（FBDB™）平台可設計具多功能與多元靶向模式之生物製劑，旨在同時活化先天與後天免疫路徑，並克服現有 anti-PD1/L1 免疫療法所面臨的挑戰。FBDB™ 平台已於多項體內腫瘤動物模型中取得概念驗證數據。漢康生技正推進一系列創新生物藥管線，透過差異化分子設計與可擴展 CMC 策略，回應重大未滿足醫療需求。
前瞻性聲明
本新聞稿包含有關漢康生技臨床開發計畫、產品候選藥物、法規策略及未來計畫之前瞻性聲明。實際結果可能因多項風險與不確定性而與前瞻性聲明所明示或暗示者有重大差異，包括臨床開發結果、法規審查決定及市場環境等。除適用法律另有規定外，漢康生技無義務更新任何前瞻性聲明。